Search results for "FAILURE"

showing 10 items of 1977 documents

Long-Term Follow-Up of Repeat Endoscopic Third Ventriculostomy in Obstructive Hydrocephalus.

2017

Endoscopic third ventriculostomy (ETV) is a safe and less-invasive treatment strategy for patients with obstructive hydrocephalus and provides excellent outcome. Nevertheless, repeat ETV in cases of ETV failure is a controversial issue.Between 1993 and 1999, 113 patients underwent a total of 126 ETVs at the Department of Neurosurgery, Mainz University Hospital. Obstructive hydrocephalus was the causative pathology in all cases. A very long-term follow-up of up to 16 years could be achieved. All medical reports of patients who received ETV were reviewed and analyzed with focus on ETV failure with following repeat ETV and its initial as well as very long-term success.Thirty-one events of ETV …

MaleReoperationmedicine.medical_specialtyPediatricsAdolescentLong term follow upObstructive hydrocephalusConstriction PathologicVentriculostomyCentral Nervous System Neoplasms03 medical and health sciencesYoung Adult0302 clinical medicinemedicineHumansTreatment FailureChildRetrospective StudiesThird Ventriclebusiness.industryCystsEndoscopic third ventriculostomyCerebral AqueductInfantUniversity hospitalSurgeryTreatment Outcome030220 oncology & carcinogenesisChild PreschoolNeuroendoscopyCerebrospinal fluid circulationTreatment strategySurgeryFemaleNeurology (clinical)NeurosurgerybusinessIntracranial Hemorrhages030217 neurology & neurosurgeryFollow-Up StudiesHydrocephalusWorld neurosurgery
researchProduct

Endovascular Aneurysm Sealing (EVAS) and Chimney EVAS in the Treatment of Failed Endovascular Aneurysm Repairs

2016

Purpose: To assess the technical success and clinical outcome of reinterventions using the Nellix Endovascular Aneurysm Sealing (EVAS) System to treat complications after endovascular aneurysm repair (EVAR). Methods: Fifteen consecutive patients (mean age 79 years; 14 men) with prior EVAR were treated with EVAS between March 2014 and December 2015 at 2 institutions. The failed prior EVARs included 13 bifurcated endografts, 1 bifurcated graft plus fenestrated cuff, and 1 tube endograft. Endoleaks were the predominant indications: type Ia in 10 and type III in 5 (3 type IIIa and 2 type IIIb). All patients presented with progressive aortic aneurysms (median 7.85-cm diameter; range 6.5–11). Ei…

MaleReoperationmedicine.medical_specialtyTime FactorsEndoleakComputed Tomography Angiographymedicine.medical_treatmentTechnical success030204 cardiovascular system & hematologyProsthesis DesignAortographyEndovascular aneurysm repair030218 nuclear medicine & medical imagingBlood Vessel Prosthesis Implantation03 medical and health sciences0302 clinical medicineAneurysmRisk FactorsGermanymedicineHumansRadiology Nuclear Medicine and imagingTreatment FailureAgedAged 80 and overbusiness.industryEndovascular Proceduresmedicine.diseaseAbdominal aortic aneurysmBlood Vessel ProsthesisSurgeryFemaleStentsSurgeryRadiologyCardiology and Cardiovascular MedicinebusinessAortic Aneurysm AbdominalJournal of Endovascular Therapy
researchProduct

Liver transplantation with grafts from septuagenarians.

2008

Abstract Background The purpose of this study was to evaluate our experience with orthotopic liver transplantation (OLT) using grafts from septuagenarians. Patients and Methods Seventeen adult patients underwent transplantation with grafts from donors 70 years of age or older during an 8-year period. Results The median donor age was 73 years (range, 70–83). Eleven (64.7%) donors had experienced at least 1 hypotensive period and received vasoactive drugs. Median cold and warm ischemia times were 7.25 hours and 35 minutes, respectively. Two recipients underwent retransplantation because of dysfunction or primary nonfunction. Morbidity rate was 47% and hospital mortality rate was 23.5%. After …

MaleReoperationmedicine.medical_specialtymedicine.medical_treatmentHospital mortalityLiver transplantationVasoactiveCause of DeathmedicineHumansHospital MortalitySurvival rateCause of deathAgedRetrospective StudiesAged 80 and overTransplantationbusiness.industryMortality rateRetrospective cohort studyTissue DonorsSurgeryLiver TransplantationTransplantationSurvival RateSurgeryFemalebusinessLiver FailureTransplantation proceedings
researchProduct

Prognostic Implications of Tissue Doppler Imaging-Derived E/Ea Ratio in Acute Heart Failure Patients

2014

Background Tissue Doppler–derived transmitral to mitral annular early diastolic velocity ratio (E/Ea), as a noninvasive estimation of left ventricular (LV) filling pressures, is a strong prognosticator in various cardiac scenarios including chronic heart failure; nevertheless, its utility for risk stratification in the whole spectrum of acute heart failure (AHF) patients remains elusive. Thus, the aim of this study was to determine the association between E/Ea ratio and 1-year mortality in nonselected patients with AHF. Methods The study included 417 consecutive patients admitted for AHF. Twenty-two patients were excluded due to nonaccurate Ea measurements, leaving the final sample to be 39…

MaleRiskmedicine.medical_specialtyMultivariate analysisHeart VentriclesDoppler echocardiographyDoppler imagingVentricular Dysfunction LeftInterquartile rangeInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingAgedHeart FailureEjection fractionmedicine.diagnostic_testbusiness.industryProportional hazards modelHeartPrognosismedicine.diseaseEchocardiography DopplerSurgeryHeart failureAcute DiseaseCardiologyEarly diastolicFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesEchocardiography
researchProduct

Usefulness of Right Ventricular to Pulmonary Circulation Coupling as an Indicator of Risk for Recurrent Admissions in Heart Failure With Preserved Ej…

2019

In recent years, the study of right ventricular (RV) to pulmonary circulation (PC) coupling in heart failure with preserved ejection fraction (HFpEF) has been a matter of special interest. Tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) ratio has emerged as a reliable noninvasive index of RV to PC coupling. Thus, we hypothesized that TAPSE/PASP would be a predictor of readmission burden in HFpEF. One thousand one hundred and twenty seven consecutive HFpEF patients discharged for acute HF were included. In 367 patients (32.6%), PASP could not be accurately measured by echocardiography, leaving the final sample size to be 760 patients. Negative …

MaleRiskmedicine.medical_specialtyPulmonary CirculationVentricular Dysfunction Right030204 cardiovascular system & hematologyPulmonary ArteryCohort Studies03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicine.arterymedicineHumansArterial Pressure030212 general & internal medicineProspective StudiesProspective cohort studyAgedAged 80 and overHeart FailurePulmonary Arterial Hypertensionright ventriculabusiness.industryStroke VolumeStroke volumeMiddle AgedPrognosispreserved ejection fractionEchocardiography Dopplersystolic excursionHospitalizationBlood pressurepulmonary circulationCohortPulmonary arteryCardiologyFemaleTricuspid ValveCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessCohort studyThe American journal of cardiology
researchProduct

Ejection Fraction by Echocardiography for a Selective Use of Magnetic Resonance After Infarction

2020

[EN] Background Cardiac magnetic resonance (CMR) permits robust risk stratification of discharged ST-segment-elevation myocardial infarction patients, but its indiscriminate use in all cases is not feasible. We evaluated the utility of left ventricular ejection fraction (LVEF) by echocardiography for a selective use of CMR after ST-segment-elevation myocardial infarction. Methods Echocardiography and CMR were performed in 1119 patients discharged for ST-segment-elevation myocardial infarction included in a multicenter registry. The prognostic power of CMR beyond echocardiography-LVEF was assessed using adjusted C statistic, net reclassification improvement index, and integrated discriminati…

MaleRiskmedicine.medical_specialtyVentricular Ejection FractionTime FactorsInfarctionMagnetic Resonance Imaging CineHeart failurePatient ReadmissionVentricular Function LeftTECNOLOGIA ELECTRONICAVentricular Dysfunction LeftPercutaneous Coronary InterventionPredictive Value of TestsInternal medicinemedicineHumansVentricular ejection fractionRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionProspective StudiesRegistriesAgedEjection fractionmedicine.diagnostic_testbusiness.industryReproducibility of ResultsMagnetic resonance imagingStroke VolumeMiddle Agedmedicine.diseasePrognosisNet reclassification improvementMyocardial infarctionTreatment OutcomeEchocardiographyMagnetic resonanceHeart failurecardiovascular systemCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessMacecirculatory and respiratory physiology
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Fetuin-A serum levels are not correlated to kidney function in long-lived subjects

2012

Objectives: Serum Fetuin A has been identified as an inhibitor of ectopic calcification. It is reduced in subjects with chronic kidney disease (CKD) and it has been proposed as a potential link between CKD and the higher prevalence of arterial calcification observed in these patients. During ageing both the stiffening of arterial wall due to calcification and a decline in kidney function are frequent. The aim of the study is to investigate if Fetuin A serum levels are associated with ageing and with AHSG T256S polymorphism. Moreover, we aim at investigate whether serum Fetuin A is correlated to kidney function in this setting of senescence. Design and Methods: 256 health long-lived subjects…

MaleSenescenceAgingmedicine.medical_specialtyFetuin Aalpha-2-HS-GlycoproteinClinical BiochemistryGene ExpressionRenal functionKidneyKidney Function TestsPolymerase Chain ReactionPolymorphism Single NucleotideEctopic calcificationElderlyInternal medicinemedicineHumansCystatin Ckidney functionAged 80 and overbiologybusiness.industryCalcinosisGeneral MedicineSerum Fetuin AKidney diseasemedicine.diseaseFetuinArterial calcificationSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaAHSG T256S polymorphismEndocrinologyFetuin A Cystatin C Elderly Kidney disease AHSGCystatin CAHSGbiology.proteinKidney Failure ChronicFemalebusinessPolymorphism Restriction Fragment LengthCalcificationKidney disease
researchProduct

Effectiveness of assisted and unassisted cough capacity in amyotrophic lateral sclerosis patients.

2017

Decreased cough capacity during a respiratory infection is one of the main causes of acute respiratory failure and hospitalisation in amyotrophic lateral sclerosis (ALS).To determine whether a respiratory measurement could identify the effectiveness of cough capacity in ALS during a respiratory infection.This was a prospective study of all ALS patients who were treated at a respiratory care unit due to a respiratory infection from 2012 to 2016. The effectiveness of unassisted and assisted coughing was evaluated and respiratory function tests were performed during the acute episode.Forty-eight ALS patients were enrolled, with only four having an effective unassisted cough. The variable which…

MaleSensitivity and Specificity03 medical and health sciences0302 clinical medicineMedicineHumansAcute respiratory failureRespiratory functionRespiratory systemAmyotrophic lateral sclerosisProspective cohort studyRespiratory Tract Infectionsbusiness.industryAmyotrophic Lateral SclerosisRespiratory infectionReproducibility of ResultsInsufflationMiddle Agedmedicine.diseaserespiratory tract diseasesRespiratory Function TestsTreatment Outcome030228 respiratory systemNeurologyCoughAnesthesiaFemaleNeurology (clinical)businessRespiratory Insufficiency030217 neurology & neurosurgeryRespiratory careAmyotrophic lateral sclerosisfrontotemporal degeneration
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct